Xin Cao

Xin Cao

Auto-generated profile, based on publicly available information

Xin Cao

College of Stomatology Chongqing Medical University Chongqing China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Microbiological Research
Verified
Journal Article
Closed access
XCXin Cao
Xin Cao
XCXing-Wang Cheng
Xing-Wang Cheng
YLYin-Ying Liu
Yin-Ying Liu
HDHongwei Dai
Hongwei Dai
Ren-You GanRen-You Gan
Ren-You Gan

5 August 2024 in The FASEB Journal
Verified
Journal Article
Closed access
ZJZhou Jianping
Zhou Jianping
SPSi‐Si Peng
Si‐Si Peng
JXjie xu
jie xu
XCXing‐Wang Cheng
Xing‐Wang Cheng
XWXiao‐Hui Wang
Xiao‐Hui Wang
XCXin Cao
Xin Cao

29 August 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
XCXin Cao
Xin Cao
SPSisi Peng
Sisi Peng
YYYing Yan
Ying Yan
JLJun Li
Jun Li
JZJianping Zhou
Jianping Zhou
JXjie xu
jie xu
Temporomandibular joint osteoarthritis (TMJOA), prevalent in adolescents and the elderly, has serious physical and psychological consequences. TMJOA is a degenerative disease of the cartilage and bone, mostly driven by inflammation, and synoviocytes are the first and most important inflammatory factor releasers. Receptor‐interacting serine/threonine‐protein kinase (RIPK1) promotes inflammatory response and cell death during an array of illnesses. This research aimed to explore the impacts of RIPK1 inhibitor therapy in TMJOA and the mechanism of RIPK1 in inducing inflammation during TMJOA. Herein, inhibition of RIPK1 suppressed the elevated levels of inflammatory factors, nuclear factor kappa B (NF‐κB), along with markers of apoptosis and necroptosis after tumour necrosis factor (TNF)‐α/cycloheximide (CHX) treatment in synoviocytes. Moreover, inflammation models were constructed in vivo through complete Freund's adjuvant (CFA) induction and disc perforation, and the findings supported that RIPK1 inhibition protected TMJ articular cartilage against progressive degradation. RIPK1 regulates NF‐κB activation via cellular inhibitor of apoptosis proteins (cIAP), apoptosis via caspase‐8, and necroptosis via RIPK3/mixed lineage kinase domain‐like (MLKL) in synoviocytes, which in turn facilitates TMJOA inflammation progression.